Form D · Biotechnology

LUTONIX INC

Maple Grove, MN · CIK 0001449814

Offering snapshot reported Dec 13, 2010 · SEC filing

Reported sold
$10M
Offering amount: $45M
Investors reported
23
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 1, 2010
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 13, 2010Initial$10,000,001No comparison23SEC filing
Nov 6, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Security to be acquired, Other
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-151789
Total Remaining to be Sold is contingent upon satisfaction of conditions precedent to a second closing.
Series C Convertible Preferred Stock and Underlying Common Stock

Source: Form D, filed Dec 13, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Chris Barry Executive
Michael Berman Director
Tony Chou Director
Kari Kubesh Executive
Debra Lano Executive
John F. Maroney Director
Jonathan Root Director
Jay W. Schmelter Director
Dennis W. Wahr, M.D. Director, Executive, Promoter
Lixiao Wang, Ph.D. Director, Executive
Kevin Wasserstein Director
Elizabeth Weatherman Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
7351 Kirkwood Lane North, Suite 138
Maple Grove, MN, 55369